Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06139224 · ClinicalTrials.gov registry record · NA

Gut Microbiota-Mediated Inflammatory Interactions Between AUD and HIV Infection

A NA study of Alcohol Use Disorder and Human Immunodeficiency Virus, sponsored by Rush University Medical Center.

Recruiting
Registry status
NA
Development phase
20
Enrollment target
1
Study location

NCT06139224 is a NA study of Alcohol Use Disorder and Human Immunodeficiency Virus that is actively recruiting participants, run by Rush University Medical Center. The registered enrollment target is 20 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06139224, a NA study of Alcohol Use Disorder and Human Immunodeficiency Virus, is actively recruiting participants, sponsored by Rush University Medical Center.

RECRUITING
Registry status
NA
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

Alcohol use disorder (AUD) has been associated with high prevalence of inflammation-associated co-morbidities in people living with HIV even those receiving effective antiretroviral therapy (ART). Our preliminary data support a model in which the combined insult of AUD and HIV on the gut, specifically on the microbiota and intestinal barrier integrity, exacerbates inflammation. Our preliminary data using intestinal organoids also suggest a potential mechanism for AUD-mediated changes in the gut barrier function during HIV; the intestines of HIV+ individuals have low resilience to alcohol induced intestinal barrier disruption caused by high levels of oxidative stress. Finally, our preliminary data also suggest a potential approach to enhance the integrity of the intestinal barrier and reduce gut derived inflammation in people living with HIV with/without AUD- short chain fatty acid prebiotics. These prebiotics prevent alcohol mediated adverse effects on the intestinal barrier and inflammation by preventing oxidative stress. These prebiotics are safe and decrease gut inflammation in humans. 20 HIV+ ART+ (10 AUD- and 10 AUD +), will be recruited for a prebiotic intervention. This is a proof-of-concept observational study to establish a causal link between microbiota-gut and HIV pathology during ART by asking whether modifying microbiota and gut milieu impacts intestinal barrier function, systemic inflammation, and brain pathology in HIV+ people. Participants will have two study visits, where stool collection and blood draw will be collected, as well as questionnaires. These participants are part of the larger observation study (n=160), which will test the hypothesis that intestines from HIV+ individuals have lower resilience to alcohol mediated gut barrier disruption than intestines from HIV-negative controls. We will recruit the following groups of participants: HIV+ ART+ AUD-; HIV+ ART+ AUD+; HIV- AUD- ; HIV- AUD+. Blood, urine, stool, and intestinal biopsies will b

Interventions

  • DIETARY_SUPPLEMENT 10 day prebiotic consumption

Study Locations (1)

Illinois

  • Ali Keshavarzian - Chicago, IL 60612

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2024-03-05
Est. Completion 2029-08-31
Phase NA

Sponsor

Rush University Medical Center

320 total trials

What the Registry Record Tells You About NCT06139224

The ClinicalTrials.gov registry entry for NCT06139224 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (94% lower). The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Alcohol Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which 10 day prebiotic consumption is the first listed.

NCT06139224 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT06139224 about?

NCT06139224 is a clinical study titled "Gut Microbiota-Mediated Inflammatory Interactions Between AUD and HIV Infection". Alcohol use disorder (AUD) has been associated with high prevalence of inflammation-associated co-morbidities in people living with HIV even those receiving effective antiretroviral therapy (ART). Our preliminary data support a model in which the combined insult of AUD and HIV on the gut, specifical...

What is the current status of trial NCT06139224?

This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2024-03-05. Estimated completion is 2029-08-31.

What conditions does trial NCT06139224 study?

This clinical trial studies the following conditions: Alcohol Use Disorder, Human Immunodeficiency Virus.

What interventions are being tested in trial NCT06139224?

The interventions under investigation include: 10 day prebiotic consumption (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06139224?

This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06139224 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alcohol Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.